• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Japan OKs OrbusNeich’s Combo Plus stent

September 25, 2019 By Danielle Kirsh

orbusneich-logoOrbusNeich Medical today said it won market approval in Japan for its Combo Plus coronary stent.

The Combo Plus stent is designed to address the risk of stent thrombosis associated with delayed healing in conventional drug-eluting stents. The Combo Plus DES uses endothelial progenitor cell capture technology and abluminal sirolimus drug elution delivered from a biodegradable matrix polymer that fully dissipates within 90 days, according to the Hong Kong-based company.

A clinical trial found that the stent was non-inferior in one-year target vessel failure compared to an everolimus-eluting stent. Combo Plus also had a better healthy stent strut coverage compared to the EES control.

“The OrbusNeich Combo DES with endoluminal biologic endothelial progenitor cell capture technology has just become the first coronary device approved for clinical use in Japan based on the Harmonee study which enrolled both Japanese and US human subjects in a single prospective randomized trial protocol,” co-principal investigator Dr. Mitchell Krucoff said in a news release. “Not only is this a huge success for the Combo DES, but it is also a first-in-kind proof of concept for the Japan-USA Harmonization By Doing program.”

The device has also been shown to promote functional endothelial layer formation for protection against thrombosis and modulates restenosis.

“The market approval of the Combo Plus coronary stent in Japan is a tremendous achievement for the entire OrbusNeich organization,” added president & CEO David Chien. “A well-coordinated global effort was required to obtain the Japan market approval of a unique product such as the Combo Plus coronary stent. We expect this approval to allow OrbusNeich to build on our strong market position in the Japan percutaneous interventional market.”

Filed Under: Drug-Device Combinations, Featured, Regulatory/Compliance, Stents Tagged With: OrbusNeich

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS